Biomarkers in Urine Samples From Patients With Wilms Tumor

Discovery and Validation of Wilms Tumor Markers Using Urine Proteomics

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01550393

Enrollment

100

Registered

2012-03-12

Start date

2012-03-31

Completion date

Unknown

Last updated

2016-07-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Kidney Cancer

Keywords

stage II Wilms tumor, stage III Wilms tumor, recurrent Wilms tumor and other childhood kidney tumors

Brief summary

RATIONALE: Studying samples of urine from patients with cancer in the laboratory may help doctors identify biomarkers related to cancer. PURPOSE: This clinical trial studies biomarkers in urine from patients with Wilms tumor.

Detailed description

OBJECTIVES: * To validate the prognostic performance of specific-candidate Wilms tumor markers by measuring their urinary concentration using enzyme-linked immunosorbent assays (ELISAs) in urine specimens collected at diagnosis from 50 patients with favorable histology Wilms tumor who relapsed and 50 patients who did not relapse. OUTLINE: Urine specimens are analyzed using enzyme-linked immunosorbent assays (ELISAs) for biomarkers.

Interventions

GENETICproteomic profiling

OTHERenzyme-linked immunosorbent assay

OTHERlaboratory biomarker analysis

OTHERmedical chart review

Study design

Observational model

CASE_ONLY

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

No minimum to 120 Years

Healthy volunteers

Inclusion criteria

DISEASE CHARACTERISTICS: * Urine specimens collected at diagnosis will be selected from patients with stage II-III Wilms tumors, with both local and non-local sites of disease relapse * Clinical patient information (urinalysis/macro, age, gender, congenital defects/syndromes, comorbidities, tumor stage, size, pathology, therapy, outcome) available PATIENT CHARACTERISTICS: * Not specified PRIOR CONCURRENT THERAPY: * Not specified

Design outcomes

Primary

Measure	Time frame
Wilms tumor biomarkers identified by ELISA	—

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026